JAGX - Jaguar Health, Inc.
IEX Last Trade
1.01
-0.010 -0.990%
Share volume: 0
Last Updated: Thu 26 Dec 2024 03:30:02 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
-0.12%
PREVIOUS CLOSE
CHG
CHG%
$1.02
-0.01
-0.98%
Fundamental analysis
21%
Profitability
8%
Dept financing
25%
Liquidity
72%
Performance
20%
Performance
5 Days
11.29%
1 Month
0 0%
3 Months
-6.36%
6 Months
-72.97%
1 Year
518.62%
2 Year
-84.03%
Key data
Stock price
$1.01
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.17 - $21.60
52 WEEK CHANGE
-$89.47
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
Company detail
CEO: Lisa A. Conte
Region: US
Website: jaguar.health
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: jaguar.health
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Jaguar Health, Inc. focuses on developing prescription medicines for people and animals with gastrointestinal distress. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera.
Recent news